研究者詳細 - 今井　則博

写真a

イマイ　ノリヒロ

今井　則博

IMAI Norihiro

所属

大学院医学系研究科総合医学専攻病態内科学助教

外部リンク

学位 1

博士(医学) （ 2016年3月名古屋大学）

学位の先頭へ▲

所属学協会 5

日本内科学会
日本消化器病学会
日本消化器内視鏡学会
日本肝臓学会
American Association for the Study of Liver Diseases

所属学協会の先頭へ▲

受賞 7

American Heart Association Postdoctoral Fellowship

2019年 American Heart Association

　詳細を見る

researchmap
Best Poster Award, Postdoc Research Day

2019年 Weill Cornell Medicine, The Postdoctoral Association
Irwin M. Arias, MD Postdoctoral Research Fellowship Award

2018年 American Liver Foundation

　詳細を見る

受賞国：アメリカ合衆国
優秀演題賞

2015年第120日本解剖学会総会・全国学術集会第92回日本生理学会大会合同大会 P1-164 肝臓特異的UBXD8ノックアウトマウスの表現型は雌マウス優位に発現する

　詳細を見る

受賞区分：国内学会・会議・シンポジウム等の賞受賞国：日本国
Presidential Poster of Distinction

2015年 American Association for the Study of Liver Disease

　詳細を見る

受賞区分：国際学会・会議・シンポジウム等の賞受賞国：アメリカ合衆国
International Young Investigator Travel Award

2015年 American Association for the Study of Liver Disease

　詳細を見る

受賞区分：国際学会・会議・シンポジウム等の賞受賞国：アメリカ合衆国
Young Investigator Award of Nagoya University Internal Medicine

2015年

　詳細を見る

受賞国：日本国

▼全件表示

受賞の先頭へ▲

論文 53

Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study.

Yamamoto T, Imai N, Kuzuya T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M

Nutrition and cancer 頁： 1 - 10 2022年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1080/01635581.2022.2049322

PubMed
Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease.

Yamamoto K, Ishizu Y, Honda T, Ito T, Imai N, Nakamura M, Kawashima H, Kitaura Y, Ishigami M, Fujishiro M

Scientific reports 12 巻 ( 1 ) 頁： 3674 2022年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1038/s41598-022-07810-3

PubMed
Obesity and myosteatosis: the two characteristics of dynapenia in patients with cirrhosis.

Sugiyama Y, Ishizu Y, Ando Y, Yokoyama S, Yamamoto K, Ito T, Imai N, Nakamura M, Honda T, Kawashima H, Ishikawa T, Ishigami M

European journal of gastroenterology & hepatology 33 巻 ( 1S Suppl 1 ) 頁： e916 - e921 2021年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：European journal of gastroenterology & hepatology

OBJECTIVE: In patients with liver cirrhosis, the clinical characteristics of dynapenia, a condition in which skeletal muscle mass is maintained but muscle strength is reduced, are not yet known. This study aimed to clarify the characteristics of dynapenia and its impact on quality of life (QOL) in patients with liver cirrhosis. METHODS: We retrospectively analyzed 116 patients with cirrhosis. Based on grip strength and skeletal muscle mass measured by the bioelectrical impedance analysis method, patients were divided into four groups: normal muscle status, dynapenia, pre-sarcopenia (a condition involving only low muscle mass), and sarcopenia. The characteristics of dynapenia and its influence on QOL were examined. RESULTS: Fourteen patients had dynapenia. Liver function did not differ among the four groups. In patients with dynapenia, BMI was highest and computed tomography attenuation of skeletal muscle at the third lumbar spine vertebra was lowest among the four groups. The percentage of patients with both BMI ≥25 kg/m2 and myosteatosis was significantly higher in patients with dynapenia [9/14 (64.3%)] than in those with sarcopenia [2/23 (8.7%), P = 0.004] and pre-sarcopenia [0/18 (0%), P < 0.001] and tended to be higher than those with normal muscle status [16/61 (26.2%), P = 0.065]. The physical QOL in patients with dynapenia was as low as that in those with sarcopenia and significantly lower than that in those with normal muscle status. CONCLUSION: Cirrhotic patients with dynapenia had high BMI and myosteatosis, and impaired physical QOL.

DOI： 10.1097/MEG.0000000000002303

Scopus

PubMed
Nuclear Receptor CoRepressors, NCOR1 and SMRT, are required for maintaining systemic metabolic homeostasis

Ritter Megan J., Amano Izuki, Imai Norihiro, De Oliveira Lorraine Soares, Vella Kristen R., Hollenberg Anthony N.

MOLECULAR METABOLISM 53 巻頁： 101315 2021年11月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Molecular Metabolism

Objective: The nuclear receptor corepressor 1 (NCOR1) and the silencing mediator of retinoic acid and thyroid hormone (SMRT, also known as NCOR2) play critical and specific roles in nuclear receptor action. NCOR1, both in vitro and in vivo specifically regulates thyroid hormone (TH) action in the context of individual organs such as the liver, and systemically in the context of the hypothalamic-pituitary-thyroid (HPT) axis. In contrast, selective deletion of SMRT in the liver or globally has shown that it plays very little role in TH signaling. However, both NCOR1 and SMRT have some overlapping roles in hepatic metabolism and lipogenesis. Here, we determine the roles of NCOR1 and SMRT in global physiologic function and find if SMRT could play a compensatory role in the regulation of TH action, globally. Methods: We used a postnatal deletion strategy to disrupt both NCOR1 and SMRT together in all tissues at 8–9 weeks of age in male and female mice. This was performed using a tamoxifen-inducible Cre recombinase (UBC-Cre-ERT2) to KO (knockout) NCOR1, SMRT, or NCOR1 and SMRT together. We used the same strategy to KO HDAC3 in male and female mice of the same age. Metabolic parameters, gene expression, and thyroid function tests were analyzed. Results: Surprisingly, adult mice that acquired NCOR1 and SMRT deletion rapidly became hypoglycemic and hypothermic and perished within ten days of deletion of both corepressors. Postnatal deletion of either NCOR1 or SMRT had no impact on mortality. NCOR1/SMRT KO mice rapidly developed hepatosteatosis and mild elevations in liver function tests. Additionally, alterations in lipogenesis, beta oxidation, along with hepatic triglyceride and glycogen levels suggested defects in hepatic metabolism. The intestinal function was intact in the NCOR1/SMRT knockout (KO) mice. The KO of HDAC3 resulted in a distinct phenotype from the NCOR1/SMRT KO mice, whereas none of the HDAC3 KO mice succumbed after tamoxifen injection. Conclusions: The KO of NCOR1 and SMRT rapidly leads to significant metabolic abnormalities that do not survive – including hypoglycemia, hypothermia, and weight loss. Hepatosteatosis rapidly developed along with alterations in hepatic metabolism suggesting a contribution to the dramatic phenotype from liver injury. Glucose production and absorption were intact in NCOR1/SMRT KO mice, demonstrating a multifactorial process leading to their demise. HDAC3 KO mice have a distinct phenotype from the NCOR1/SMRT KO mice—which implies that NCOR1/SMRT together regulate a critical pathway that is required for survival in adulthood and is separate from HDAC3.

DOI： 10.1016/j.molmet.2021.101315

Web of Science

Scopus

PubMed
Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes

Imai Norihiro, Yokoyama Shinya, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishigami Masatoshi

ANTICANCER RESEARCH 41 巻 ( 11 ) 頁： 5817 - 5820 2021年11月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Anticancer Research

Aim: Novel glass membrane pumping emulsification devices (GMDs) enable the formation of a high-percentage water-in-oil emulsion with homogeneous and stable droplets. Although GMDs are expected to improve therapeutic effects in transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), clinical outcomes are not yet available. Patients and Methods: A total of 26 patients with unresectable HCC who underwent TACE using a GMD were analyzed retrospectively. Ethiodized oil was mixed with epirubicin solution using a GMD. The emulsion was injected into the tumor-feeding artery, followed by embolization. Results: The median size of HCCs was 28 (range=15-60) mm, and 15 nodules were solitary. Overall treatment effects were complete response in 18 cases (90%) and partial response in two (10%). The local recurrence rate at 6 months was 24.2%. No major complication was observed except for grade 4 elevations of liver enzymes in one case. Conclusion: TACE using a GMD is effective and safe in clinical practice.

DOI： 10.21873/anticanres.15399

Web of Science

Scopus

PubMed
The absence of large portal collateral vessels is concerned with spontaneous improvement of cirrhotic portal vein thrombosis.

Yokoyama S, Ishizu Y, Honda T, Imai N, Ito T, Yamamoto K, Tomoyuki T, Ishigami M

Hepatology research : the official journal of the Japan Society of Hepatology 2021年10月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1111/hepr.13725

PubMed
Immune-related liver injury is a poor prognostic factor in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.

Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M

Cancer investigation 頁： 1 - 31 2021年10月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1080/07357907.2021.1994586

PubMed
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

Ito Takanori, Ishigami Masatoshi, Yamamoto Takafumi, Mizuno Kazuyuki, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Kawashima Hiroki, Yasuda Satoshi, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Nishio Naoki, Maeda Osamu, Kato Masashi, Hashimoto Naozumi, Hibi Hideharu, Kodera Yasuhiro, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Shimoyama Yoshie, Fujishiro Mitsuhiro

HEPATOLOGY INTERNATIONAL 15 巻 ( 5 ) 頁： 1278 - 1287 2021年10月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Hepatology International

Background: The clinical course of liver injury induced by immune checkpoint inhibitors (ICIs) varies among individuals, and there were few reports on the therapeutic effects of corticosteroids based on the patterns of liver injury. Methods: We evaluated the characteristics and clinical course of immune-related liver injury in 1214 patients treated with ICIs for advanced malignancies except for hepatocellular carcinoma between August 2014 and May 2021. Results: During the follow-up period (median, 252 days), 58 patients (4.8%) had an immune-related liver injury (≥ Grade 3). The liver-injury patterns were hepatocellular (n = 26, 44.8%), mixed (n = 11, 19.0%), or cholestatic (n = 21, 36.2%), and the median time to onset of liver injury was 39, 81, and 53 days, respectively; the hepatocellular pattern occurred earlier than the other types (p = 0.047). Corticosteroids were administered to 30 (51.7%) patients; while liver injury was improved in almost all patients with the hepatocellular pattern (n = 13/14, 92.9%), that failed to show improvement in over half of the patients with the non-hepatocellular patterns, and three patients with mixed patterns needed secondary immunosuppression with mycophenolate mofetil. Liver biopsies performed in 13 patients mainly showed lobular injury, endothelialitis, and spotty necrosis with infiltration of T cells positive for CD3 and CD8, but not CD4 or CD20. Conclusion: The incidence pattern and therapeutic response to corticosteroids in immune-related liver injury differ according to the injury type. Although corticosteroids were effective for the hepatocellular pattern, an additional strategy for refractory non-hepatocellular patterns is needed.

DOI： 10.1007/s12072-021-10238-y

Web of Science

Scopus

PubMed
USEFULNESS OF CORE I97L IN PREDICTING THE EFFICACY OF NUCLEOS(T)IDE ANALOGUE THERAPY IN PATIENTS WITH HEPATITIS B

TakashiHonda, MasatoshiIshigami, ShinyaYokoyama, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Ishizu Yoji, Ishikawa Tetsuya, Fujishiro Mitsuhiro

HEPATOLOGY 74 巻頁： 468A - 469A 2021年10月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）

Web of Science
The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophiliaHCC after HCV eradication in hemophilia.

Inukai Y, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M

Annals of hepatology 27 巻 ( 1 ) 頁： 100545 2021年9月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Annals of Hepatology

Introduction and objectives: Hepatitis C virus (HCV) infections in patients with hemophilia lead to the development of hepatocellular carcinoma (HCC) at a relatively younger age than that in patients without hemophilia. Although recent progress in direct-acting-antivirals has facilitated a high rate of sustained virological response (SVR), the clinical influence of HCV eradication in hemophilia patients remains unclear. This study aimed to compare the clinical outcomes of SVR against HCV in patients with and without hemophilia. Patients and methods: The study enrolled 699 patients who achieved SVR after HCV antiviral treatment. Patients were divided into two groups: 78 patients with hemophilia (H group) and 621 patients without hemophilia (NH group). We evaluated patient characteristics, clinical outcomes, and the cumulative incidence of HCC after SVR. Results: Compared with the NH group, patients in the H-group were significantly younger and had a lower hepatic fibrosis score. No difference was found in the incidence of liver-related disease or overall death between the two groups over a mean follow-up period of 7 years. Four patients in the H group and 36 patients in the NH group were diagnosed with HCC after SVR. Multivariate analysis showed that male sex, age, and cirrhosis were significant risk factors for HCC incidence. There was no significant difference in the cumulative incidence of HCC after propensity-score matching adjusting for the risk factors of HCC between the two groups. Conclusion: Hemophilia is not a significant risk factor for hepatocarcinogenesis after SVR against HCV.

DOI： 10.1016/j.aohep.2021.100545

Scopus

PubMed
Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis

Muto Hisanori, Ito Takanori, Tanaka Taku, Yokoyama Shinya, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Maeda Keiko, Honda Takashi, Ishikawa Tetsuya, Kato Asuka, Ohshiro Taichi, Kano Fumiya, Yamamoto Akihito, Sakai Kiyoshi, Hibi Hideharu, Ishigami Masatoshi, Fujishiro Mitsuhiro

SCIENTIFIC REPORTS 11 巻 ( 1 ) 頁： 18778 2021年9月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Scientific Reports

Non-alcoholic steatohepatitis (NASH) occurrence has been increasing and is becoming a major cause of liver cirrhosis and liver cancer. However, effective treatments for NASH are still lacking. We examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth (SHED-CM) on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet (WD) and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis. We showed that repeated intravenous administration of SHED-CM significantly ameliorated histological liver fibrosis and inflammation in a murine NASH model. SHED-CM inhibited parenchymal cell apoptosis and reduced the activation of inflammatory macrophages. Gene expression of pro-inflammatory and pro-fibrotic mediators (such as Tnf-α, Tgf-β, and Ccl-2) in the liver was reduced in mice treated with SHED-CM. Furthermore, SHED-CM protected intestinal tight junctions and maintained intestinal barrier function, while suppressing gene expression of the receptor for endotoxin, Toll-like receptor 4, in the liver. SHED-CM promoted the recovery of Caco-2 monolayer dysfunction induced by IFN-γ and TNF-α in vitro. Our findings suggest that SHED-CM may inhibit NASH fibrosis via the gut-liver axis, in addition to its protective effect on hepatocytes and the induction of macrophages with unique anti-inflammatory phenotypes.

DOI： 10.1038/s41598-021-98254-8

Web of Science

Scopus

PubMed
Revisiting Prognosis After Liver Transplant in Patients Positive for Hepatitis C Virus: Focus on Hepatitis C Recurrence-Unrelated Complications

Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Kamei Hideya, Ogura Yasuhiro, Fujishiro Mitsuhiro

EXPERIMENTAL AND CLINICAL TRANSPLANTATION 19 巻 ( 9 ) 頁： 935 - 942 2021年9月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Experimental and Clinical Transplantation

Objectives: In this study, we revisited the reasons for poorer prognosis after liver transplant in patients with hepatitis C virus, whose main causes of death were generally known to be recurrent disease. Materials and Methods: Between April 2003 and March 2017, among 132 patients who underwent liver transplant because of liver cirrhosis at our institution, 40 patients (30.3%) were positive for hepatis C virus. We retrospectively compared the overall survival after liver transplant in patients with and without hepatitis C virus infection. Furthermore, we investigated the causes of death in transplant recipients with hepatitis C virus infections. Results: In patients with hepatitis C virus infection, overall survival was 82.2%, 75.2%, and 50.8% at 1, 5, and 10 years, respectively, after liver transplant; these results were lower than those in patients without infection (94.5%, 87.0%, and 87.0% at 1, 5, and 10 years, respectively; P = .001). Among 40 patients with positive infection, 14 patients died after liver transplant. A main reason for death was hepatocellular carcinoma recurrence (3 patients). Surprisingly, only 1 patient died from hepatitis C virus-related complication (fibrosing cholestatic hepatitis); the remaining 10 patients died from reasons other than hepatitis C virus disease progression. Conclusions: Our results suggest that clinicians should not only be aware of hepatitis C virus recurrence but should also be aware of other unrelated complications in transplant recipients who are positive for this virus.

DOI： 10.6002/ect.2021.0197

Web of Science

Scopus

PubMed
Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.

Imai N, Nicholls HT, Alves-Bezerra M, Li Y, Ivanova AA, Ortlund EA, Cohen DE

Hepatology (Baltimore, Md.) 2021年8月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1002/hep.32122

PubMed
The impact of hepatitis C virus eradication on hepatocarcinogenesis in haemophiliacs

Inukai Yosuke, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishigami Masatoshi

JOURNAL OF HEPATOLOGY 75 巻頁： S787 - S788 2021年7月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）

Web of Science
Thioesterase superfamily member 1 undergoes stimulus-coupled conformational reorganization to regulate metabolism in mice

Li Yue, Imai Norihiro, Nicholls Hayley T., Roberts Blaine R., Goyal Samaksh, Krisko Tibor I., Ang Lay-Hong, Tillman Matthew C., Roberts Anne M., Baqai Mahnoor, Ortlund Eric A., Cohen David E., Hagen Susan J.

NATURE COMMUNICATIONS 12 巻 ( 1 ) 頁： 3493 2021年6月

　詳細を見る

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Nature Communications

In brown adipose tissue, thermogenesis is suppressed by thioesterase superfamily member 1 (Them1), a long chain fatty acyl-CoA thioesterase. Them1 is highly upregulated by cold ambient temperature, where it reduces fatty acid availability and limits thermogenesis. Here, we show that Them1 regulates metabolism by undergoing conformational changes in response to β-adrenergic stimulation that alter Them1 intracellular distribution. Them1 forms metabolically active puncta near lipid droplets and mitochondria. Upon stimulation, Them1 is phosphorylated at the N-terminus, inhibiting puncta formation and activity and resulting in a diffuse intracellular localization. We show by correlative light and electron microscopy that Them1 puncta are biomolecular condensates that are inhibited by phosphorylation. Thus, Them1 forms intracellular biomolecular condensates that limit fatty acid oxidation and suppress thermogenesis. During a period of energy demand, the condensates are disrupted by phosphorylation to allow for maximal thermogenesis. The stimulus-coupled reorganization of Them1 provides fine-tuning of thermogenesis and energy expenditure.

DOI： 10.1038/s41467-021-23595-x

Web of Science

Scopus

PubMed
Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.

Yamamoto T, Imai N, Yamamoto K, Ito T, Ishizu Y, Honda T, Okamoto S, Kanematsu T, Suzuki N, Matsushita T, Ishigami M, Fujishiro M

Anticancer research 41 巻 ( 5 ) 頁： 2569 - 2573 2021年5月

　詳細を見る

掲載種別：研究論文（学術雑誌）

DOI： 10.21873/anticanres.15035

PubMed
Impact of visceral fat accumulation on the prognosis of patients with cirrhosis

Ishizu Yoji, Ishigami Masatoshi, Honda Takashi, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

CLINICAL NUTRITION ESPEN 42 巻頁： 354 - 360 2021年4月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Clinical Nutrition ESPEN

DOI： 10.1016/j.clnesp.2021.01.008

Web of Science

Scopus

PubMed

researchmap
Progression After Molecular Targeted Agents: Hepatic Arterial Changes and Transarterial Chemoembolization in Hepatocellular Carcinoma.

Matsuda N, Imai N, Kuzuya T, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Fujishiro M

In vivo (Athens, Greece) 35 巻 ( 2 ) 頁： 1185 - 1189 2021年3月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：In Vivo

DOI： 10.21873/invivo.12367

Scopus

PubMed

researchmap
Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia

Yamamoto Takafumi, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

HAEMOPHILIA 27 巻 ( 1 ) 頁： 100 - 107 2021年1月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Haemophilia

DOI： 10.1111/hae.14220

Web of Science

Scopus

PubMed

researchmap
The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC

Ito Takanori, Ishigami Masatoshi, Morooka Hikaru, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Nishimura Daisaku, Tada Toshifumi, Yasuda Satoshi, Toyoda Hidenori, Kumada Takashi, Fujishiro Mitsuhiro

SCIENTIFIC REPORTS 10 巻 ( 1 ) 頁： 17812 2020年10月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Scientific Reports

DOI： 10.1038/s41598-020-74732-3

Web of Science

Scopus

PubMed

researchmap
Allosteric regulation of thioesterase superfamily member 1 by lipid sensor domain binding fatty acids and lysophosphatidylcholine

Tillman Matthew C., Imai Norihiro, Li Yue, Khadka Manoj, Okafor C. Denise, Juneja Puneet, Adhiyaman Akshitha, Hagen Susan J., Cohen David E., Ortlund Eric A.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 117 巻 ( 36 ) 頁： 22080 - 22089 2020年9月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Proceedings of the National Academy of Sciences of the United States of America

DOI： 10.1073/pnas.2003877117

Web of Science

Scopus

PubMed

researchmap
Them1 Binds to Free Fatty Acids and is Allosterically Regulated by Lysophosphatidylcholine to Control Fatty Acyl-CoA Hydrolysis in Brown Adipose Tissue

Tillman Matthew, Li Yue, Khadka Manoj, Imai Norihiro, Adhiyaman Akshitha, Juneja Puneet, Hagen Susan, Cohen David, Ortlund Eric

FASEB JOURNAL 34 巻 2020年4月

　詳細を見る

掲載種別：研究論文（学術雑誌）

DOI： 10.1096/fasebj.2020.34.s1.07311

Web of Science

researchmap
Thioesterase Superfamily Member 1 Undergoes Stimulus-coupled Reorganization to Regulate Metabolic Activity in Brown Adipose Tissue

Li Yue, Imai Norihiro, Goyal Samaksh, Nicholls Hayley, Krisko Tibor, Baqai Mahnoor, Ang Lay-Hong, Tillman Matthew, Ortlund Eric, Cohen David, Hagen Susan

FASEB JOURNAL 34 巻 2020年4月

　詳細を見る

掲載種別：研究論文（学術雑誌）

DOI： 10.1096/fasebj.2020.34.s1.04503

Web of Science

researchmap
Hepatology Highlights.

Shah PA, Lau DTY, Russo NW, Brown RS Jr, Maiers JL, Schwartz RE, Imai N, Krisko TI, Navarro-Corcuera A, Jalan-Sakrikar N, Pisa JF, Jesudian AB, Tafesh ZH, Fortune BE, Kostallari E

Hepatology (Baltimore, Md.) 71 巻 ( 1 ) 頁： 1 - 3 2020年1月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

DOI： 10.1002/hep.31072

PubMed

researchmap
Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD

Imai Norihiro, Cohen David E.

HEPATOLOGY 68 巻 ( 6 ) 頁： 2062 - 2065 2018年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Hepatology

DOI： 10.1002/hep.30206

Web of Science

Scopus

PubMed

researchmap
Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model

Imai Norihiro, Suzuki Michitaka, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Ishikawa Tetsuya, Goto Hidemi, Fujimoto Toyoshi

HISTOCHEMISTRY AND CELL BIOLOGY 148 巻 ( 3 ) 頁： 219 - 227 2017年9月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Histochemistry and Cell Biology

DOI： 10.1007/s00418-017-1572-6

Web of Science

Scopus

PubMed

researchmap
Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet

Imai Norihiro, Suzuki Michitaka, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Abe Takaya, Shioi Go, Goto Hidemi, Fujimoto Toyoshi

PLOS ONE 10 巻 ( 5 ) 頁： e0127114 2015年5月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：PLoS ONE

DOI： 10.1371/journal.pone.0127114

Web of Science

Scopus

PubMed

researchmap
Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H

World journal of hepatology 6 巻 ( 12 ) 頁： 844 - 50 2014年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：World Journal of Hepatology

DOI： 10.4254/wjh.v6.i12.844

Scopus

PubMed

researchmap
The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

Kuzuya T

Acta Hepatologica Japonica 54 巻 ( 7 ) 頁： 505 - 506 2013年5月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT. 

DOI： 10.2957/kanzo.54.505

Scopus

researchmap
Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Gut and liver 7 巻 ( 2 ) 頁： 246 - 51 2013年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Gut and Liver

DOI： 10.5009/gnl.2013.7.2.246

Scopus

PubMed

researchmap
Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAX™ instrument navigator

Kuzuya T

Acta Hepatologica Japonica 54 巻 ( 12 ) 頁： 850 - 853 2013年

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

We performed percutaneous radio frequency ablation (RFA) therapy by two-step insertion method using VirtuTRAXTM (GE Healthcare, USA) instrument navigator. Subjects were 16 patients (23 nodules) with hepatocellular carcinoma. VirtuTRAXTM position sensor was attached to the hilt of 14-gauge outer needle. In all cases, we could perform 17- gauge Cool-tip RFA without the positional gap between the virtual tract and the actual needle which was caused by the deflection of the needle. The reasons without causing the positional gap were that the outer needle was more rigid than Cool-tip needle, and that it was inserted using initial insertion of a 21-gauge guided needle. RFA by two-step insertion method using VirtuTRAXTM is suggested to be more safe and effective than conventional RFA.

DOI： 10.2957/kanzo.54.850

Scopus

researchmap
An Increase in Lesion Density can Predict Lower Local Recurrence after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Imai Norihiro, Katano Yoshiaki, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Itoh Akihiro, Hirooka Yoshiki, Goto Hidemi

HEPATO-GASTROENTEROLOGY 60 巻 ( 125 ) 頁： 965 - 970 2013年

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Hepato-Gastroenterology

DOI： 10.5754/hge121229

Web of Science

Scopus

PubMed

researchmap
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

ARASE Yasuji, SUZUKI Yoshiyuki, SUZUKI Fumitaka, AKUTA Norio, SEZAKI Hitomi, KAWAMURA Yusuke, KOBAYASHI Masahiro, IMAI Norihiro, SEKO Yuya, HOSAKA Tetsuya, MATSUMOTO Naoki, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology 42 巻 ( 8 ) 頁： 750 - 756 2012年8月

　詳細を見る

掲載種別：研究論文（学術雑誌）
ミリプラチン動注化学療法を併用したラジオ波凝固療法

今井則博, 池田健次, 瀬古裕也, 原祐, 大野敦司, 松本直樹, 川村祐介, 保坂哲也, 小林正宏, 斎藤聡, 瀬崎ひとみ, 芥田憲夫, 鈴木文孝, 鈴木義之, 荒瀬康司, 熊田博光

肝臓 53 巻 ( 6 ) 頁： 351-354 - 354 2012年6月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人　日本肝臓学会

Miriplatin is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We retrospectively evaluated the efficacy of combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for HCC in 11 patients. Immediately after transcatheter arterial infusion chemotherapy using miriplatin, we performed radiofrequency ablation. The greatest long-axis and short-axis dimensions of the area coagulated after combination therapy were 42 mm (35-80 mm) and 34 mm (32-60 mm), respectively. During follow-up (median 12 months), there was no recurrence from the same subsegment. No serious adverse events were observed. These results suggested that using the combination therapy, it is possible to finish one treatment session for patient with HCC. 

DOI： 10.2957/kanzo.53.351

researchmap
Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126mg/dL

MATSUMOTO Naoki, ARASE Yasuji, SEKO Yuya, IMAI Norihiro, KAWAMURA Yusuke, SEZAKI Hitomi, HOSAKA Tetsuya, AKUTA Norio, KOBAYASHI Mariko, KOBAYASHI Masahiro, SUZUKI Yoshiyuki, SAITO Satoshi, SUZUKI Fumitaka, IKEDA Kenji, KUMADA Hiromitsu, AIDA Kaoru, KOBAYASHI Tetsuro

Hepatology research : the official journal of the Japan Society of Hepatology 42 巻 ( 6 ) 頁： 558 - 563 2012年6月

　詳細を見る

掲載種別：研究論文（学術雑誌）
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderlv patients

ARASE Yasuji, KOBAYASHI Mariko, SUZUKI Fumitaka, SUZUKI Yoshiyuki, KAWAMURA Yusuke, AKUTA Norio, IMAI Norihiro, KOBAYASHI Masahiro, SEZAKI Hitomi, MATSUMOTO Naoki, SAITO Satoshi, HOSAKA Tetsuya, IKEDA Kenji, KUMADA Hiromitsu, OHMOTO Yuki, AMAKAWA Kazuhisa, HSIEH Shiun Dong, OGAWA Kyoko, TANABE Maho, TSUJI Hiroshi, KOBAYASHI Tetsuro

Hepatology research : the official journal of the Japan Society of Hepatology 42 巻 ( 3 ) 頁： 264 - 272 2012年3月

　詳細を見る

掲載種別：研究論文（学術雑誌）
Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Japanese journal of clinical oncology 42 巻 ( 3 ) 頁： 175 - 82 2012年3月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Japanese Journal of Clinical Oncology

DOI： 10.1093/jjco/hyr189

Scopus

PubMed

researchmap
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.

Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H

The American journal of gastroenterology 107 巻 ( 2 ) 頁： 253 - 61 2012年2月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：American Journal of Gastroenterology

DOI： 10.1038/ajg.2011.327

Scopus

PubMed

researchmap
慢性腎不全合併肝細胞癌に対するミリプラチン肝動脈化学療法の安全性と有効性

今井則博, 池田健次, 瀬古裕也, 松本直樹, 川村祐介, 保坂哲也, 小林正宏, 斎藤聡, 瀬崎ひとみ, 芥田憲夫, 鈴木文孝, 鈴木義之, 荒瀬康司, 熊田博光

日本消化器病學會雜誌 = The Japanese journal of gastro-enterology 108 巻 ( 11 ) 頁： 1872-1878 - 1878 2011年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：一般財団法人日本消化器病学会

ミリプラチン投与症例より投与前の推定クレアチニン・クリアランス（以下推定Ccr）が60ml/min未満67例，60ml/min以上95例を対象とし推定Ccrの変化，副作用，有効性について検討した．慢性腎不全群における治療後2カ月の間の推定Ccr値（中央値）は治療前後の補液による上昇の他に明らかな低下を認めなかった（治療前；46ml/min，1週間後；52ml/min，1カ月後；48ml/min，2カ月後；45ml/min，P<0.0001）．ミリプラチン投与による重篤な副作用は認められなかった．ミリプラチンは慢性腎不全を合併した肝細胞癌に対する白金製剤として，その安全性が示唆された． 

DOI： 10.11405/nisshoshi.108.1872

researchmap
Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure

Imai N.

Journal of Japanese Society of Gastroenterology 108 巻 ( 11 ) 頁： 1872-1878 2011年11月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）

Scopus
Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

ARASE Yasuji, SUZUKI Fumitaka, KAWAMURA Yusuke, SUZUKI Yoshiyuki, KOBAYASHI Masahiro, MATSUMOTO Naoki, AKUTA Norio, SEZAKI Hitomi, HOSAKA Tetsuya, OGAWA Kyoko, IMAI Norihiro, SEKO Yuya, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology 41 巻 ( 10 ) 頁： 946 - 954 2011年10月

　詳細を見る

掲載種別：研究論文（学術雑誌）
A case of intractable hepatic encephalopathy successfully treated by oral administration of vancomycin hydrochloride, with subsequent improvement of hepatic function reserve enabling transcatheter arterial chemoembolization against hepatocellular carcinoma

Kuzuya T.

Japanese Journal of Cancer and Chemotherapy 38 巻 ( 6 ) 頁： 995 - 997 2011年6月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Japanese Journal of Cancer and Chemotherapy

Scopus
Clearance of hepatitis b surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B

Hosaka T

Acta Hepatologica Japonica 52 巻 ( 4 ) 頁： 255 - 257 2011年6月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

Clearance of HBsAg is considered the ultimate goal in the treatment for chronic hepatitis B. We analyzed clinical factors associated with HBsAg clearance during long-term nucleot(s)ide analogue treatment. By univariate analysis, HBV genotype, family history of HBV infection, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were significant predictive factors. By multivariate analysis, HBV genotype, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were independent and significant predictive factors of HBsAg clearance. We conclude that patients with genotype A have high probability of HBsAg clearance, and it seems that not only the antiviral potential of nucleot(s)ide analogue but host immune response is needed to achieve HBsAg clearance. 

DOI： 10.2957/kanzo.52.255

Scopus

researchmap
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Arase Y

Hepatology Research 41 巻 ( 6 ) 頁： 524 - 529 2011年6月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Hepatology Research

DOI： 10.1111/j.1872-034X.2011.00798.x

Scopus

researchmap
Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.

Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Liver international : official journal of the International Association for the Study of the Liver 31 巻 ( 5 ) 頁： 692 - 9 2011年5月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Liver International

DOI： 10.1111/j.1478-3231.2011.02480.x

Scopus

PubMed

researchmap
Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Suzuki Y

Acta Hepatologica Japonica 52 巻 ( 2 ) 頁： 147 - 149 2011年4月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

To further improve therapeutic effect on chronic hepatitis C, we have administered NS3 inhibitor and NS5A inhibitor together, and examined effects of early antiviral agent therapy. The subjects were five cases where interferon is ineffective (null responders). The NS5A and NS3 inhibitors are oral drugs and were daily administered for 24 weeks. Figure 1 shows time-dependent change of the number of viruses after the therapy started, and rapid decrease of viruses is recognized. Within 12 hours, HCV-RNA decreased by more than 2 log IU/ml in every patient. Two patients became negative for the virus by the 15th day after the therapy started. Furthermore, 80% of cases by the 28th day and all the cases by the 56th day became negative. The new therapy has manifested excellent early antiviral effect. 

DOI： 10.2957/kanzo.52.147

Scopus

researchmap
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Arase Y, Suzuki Y, Suzuki F, Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M, Kumada H

Internal medicine (Tokyo, Japan) 50 巻 ( 19 ) 頁： 2083 - 8 2011年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Internal Medicine

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy of natural human interferon-beta and ribavirin for patients for whom prior interferon therapy was discontinued due to depression induced by interferon-alpha. Methods Inclusion criteria were as follows; 1) HCV-genotype 1b, 2) serum HCV RNA level of ≥100 KIU/mL, 3) stopping the prior interferon-alpha monotherapy or combination therapy of interferon-alpha and ribavirin due to the appearance of depression. A total of 14 were enrolled in this prospective cohort study. The treatment period of combination therapy was 48 weeks. Depression states, reflected by Beck depression inventories and Hamilton depression rating scale, were assessed during combination therapy. Nonparametric procedures were employed for the analysis of background features of the patients with sustained virological response (SVR) and without SVR. A p value of <0.05 was considered to indicate a significant difference. Results Five of 14 patients (37.5%) had SVR by the intention to treat analysis. The SVR rate in patients who showed negative HCV RNA at 12 and 24 weeks after the initiation of combination therapy was 100% (4/4) and 83.3% (5/6), respectively. All of the patients continued the combination therapy owing to disappearance of severely adverse events contained the exacerbation of depression. Combination therapy did not yield a statistical difference in Beck depression inventories and Hamilton depression rating scale. Conclusion The combination therapy of IFN-beta and ribavirin is a possible therapy selection for the patients for whom interferon therapy was discontinued due to depression induced by interferon-alpha. 

DOI： 10.2169/internalmedicine.50.5767

Scopus

PubMed

researchmap
Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Oncology 80 巻 ( 3-4 ) 頁： 188 - 94 2011年

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oncology

DOI： 10.1159/000328749

Scopus

PubMed

researchmap
Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation : A retrospective study of hepatitis C virus-related liver cancer

IKEDA Kenji, KOBAYASHI Masahiro, SEKO Yuya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yusuke, SEZAKI Hitomi, HOSAKA Tetsuya, AKUTA Norio, SAITOH Satoshi, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology 40 巻 ( 12 ) 頁： 1168-1175 2010年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）
Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and child-pugh B liver cirrhosis

Imai N

Acta Hepatologica Japonica 51 巻 ( 12 ) 頁： 758 - 760 2010年12月

　詳細を見る

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Acta Hepatologica Japonica

Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting severe liver cirrhosis, there is no prospective data regarding clinical toxicity of miriplatin in HCC patients with severe cirrhosis. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 34 HCC patients with severe liver cirrhosis (Child-Pugh grade B). An anti-tumor effect of complete response was achieved in 8 of 34 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safety for HCC patients with Child-Pugh B liver cirrhosis. 

DOI： 10.2957/kanzo.51.758

Scopus

researchmap
A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy

Imai N.

Japanese Journal of Cancer and Chemotherapy 37 巻 ( 3 ) 頁： 527 - 529 2010年3月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Japanese Journal of Cancer and Chemotherapy

Scopus
High Incidence of Colonic Perforation During Colonoscopy in Hemodialysis Patients With End-Stage Renal Disease

Imai Norihiro, Takeda Kinichi, Kuzuya Teiji, Utsunomiya Setsuo, Takahashi Hiroshi, Kasuga Hirotake, Asai Masami, Yamada Michiko, Tanikawa Yutaka, Goto Hidemi

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 8 巻 ( 1 ) 頁： 55 - 59 2010年1月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Clinical Gastroenterology and Hepatology

DOI： 10.1016/j.cgh.2009.09.029

Web of Science

Scopus

PubMed

researchmap
A case of hepatitis b-related multiple hepatocellular carcinomas, most of which lead to necrosis possibly due to the implantation of an arterial infusion catheter

Kuzuya T.

Japanese Journal of Cancer and Chemotherapy 36 巻 ( 12 ) 頁： 2377 - 2379 2009年11月

　詳細を見る

掲載種別：研究論文（学術雑誌）出版者・発行元：Japanese Journal of Cancer and Chemotherapy

Scopus

▼全件表示

論文の先頭へ▲

書籍等出版物 2

肝癌診療ハンドブックケースで学ぶ集学的治療のコツとセンス

今井則博, 池田健次（担当：共著 , 範囲: ケースカンファレンス, 肝癌スクリーニングフローチャート, 各種モダリティの長所と短所, EOB-MRI肝細胞相でのみ低信号結節として指摘できる病変の診断, 肝動脈化学塞栓療法(TACE) 他）

南江堂 2012年
劇症肝炎, 病気がみえる vol. 1 消化器第4版

今井則博, 荒瀬康司（担当：共著 , 範囲: 劇症肝炎）

メディックメディア 2010年

　詳細を見る

記述言語：日本語

researchmap

書籍等出版物の先頭へ▲

講演・口頭発表等 16

SUPPRESSION OF FATTY ACID OXIDATION BY THIOESTERASE SUPERFAMILY MEMBER 2 IN SKELETAL MUSCLE PROMOTES HEPATIC STEATOSIS AND INSULIN RESISTANCE

Imai Norihiro, Alves-Bezerra Michele, Li Yingxia, Cohen David E.

HEPATOLOGY

　詳細を見る

開催年月日： 2019年10月

記述言語：英語会議種別：口頭発表（一般）
Muscle-Specific Metabolic Regulation By Thioesterase Superfamily Member 2 in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Imai Norihiro, Cohen David E.

HEPATOLOGY

　詳細を見る

開催年月日： 2018年10月

記述言語：英語会議種別：口頭発表（一般）
Hepatocyte-Specific Depletion of Ubiquitin Regulatory X Domain-Containing 8 (UBXD8) Induces Marked Fibrosis in Mice Fed a Short-Term Non-Alcoholic Steatohepatitis (NASH) Model Diet

Imai Norihiro, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Fujimoto Toyoshi, Goto Hidemi

HEPATOLOGY

　詳細を見る

開催年月日： 2016年10月

記述言語：英語会議種別：口頭発表（一般）
Hepatocyte-specific depletion of UBXD8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model

Imai Norihiro, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Fujimoto Toyoshi, Goto Hidemi

HEPATOLOGY

　詳細を見る

開催年月日： 2015年10月

記述言語：英語会議種別：口頭発表（一般）
Hepatocyte-specific deletion of UBXD8 induces periportal steatosis after high-fat diet feeding

Imai Norihiro, Suzuki Michitaka, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Fujimoto Toyoshi, Goto Hidemi

HEPATOLOGY

　詳細を見る

開催年月日： 2014年

記述言語：英語会議種別：口頭発表（一般）
Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD

Imai Norihiro, Cohen David E

HEPATOLOGY 2018年12月 Hepatology

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
Thioesterase Superfamily Member 1 Undergoes Stimulus-coupled Reorganization to Regulate Metabolic Activity in Brown Adipose Tissue

Li Yue, Imai Norihiro, Goyal Samaksh, Nicholls Hayley, Krisko Tibor, Baqai Mahnoor, Ang Lay-Hong, Tillman Matthew, Ortlund Eric, Cohen David, Hagen Susan

FASEB JOURNAL 2020年4月

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
GUT MICROBIOTA ASSOCIATED WITH THE DIFFERENCE BETWEEN PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE

Honda Takashi, Ishigami Masatoshi, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Ishizu Yoji, Fujishiro Mitsuhiro

HEPATOLOGY 2020年11月

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
IMPROVEMENT OF LIVER FUNCTIONAL RESERVE AFTER SVR IN HCV-PATIENTS WITH COMPENSATED, SEVERE FIBROSIS BY IFN-FREE, DAA COMBINATION TREATMENT-IMPACT OF PRETREATMENT SERUM AFP LEVELS

Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

HEPATOLOGY 2020年11月

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
MODELING NAFLD IN HIGH FAT FED MICE: IDENTIFICATION OF A THRESHOLD VALUE FOR HEPATIC STEATOSIS AND METABOLIC DYSFUNCTION

Imai Norihiro, Cohen David E

HEPATOLOGY 2020年11月

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
SAFETY AND EFFICACY OF PERCUTANEOUS RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA PATIENTS WITH HEMOPHILIA

Yamamoto Takafumi, Ishigami Masatoshi, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Lshizu Yoji, Honda Takashi, Fujishiro Mitsuhiro

HEPATOLOGY 2020年11月

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
Them1 Binds to Free Fatty Acids and is Allosterically Regulated by Lysophosphatidylcholine to Control Fatty Acyl-CoA Hydrolysis in Brown Adipose Tissue

Tillman Matthew, Li Yue, Khadka Manoj, Imai Norihiro, Adhiyaman Akshitha, Juneja Puneet, Hagen Susan, Cohen David, Ortlund Eric

FASEB JOURNAL 2020年4月

　詳細を見る

記述言語：英語会議種別：口頭発表（一般）

researchmap
GUT MICROBIOTA ASSOCIATED WITH THE DIFFERENCE BETWEEN PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE

Honda Takashi, Ishigami Masatoshi, Yamamoto Kenta, Ito Takanori, Imai Norihiro, Ishizu Yoji, Fujishiro Mitsuhiro

HEPATOLOGY 2020年11月

　詳細を見る

会議種別：口頭発表（一般）
Thioesterase Superfamily Member 1 Undergoes Stimulus-coupled Reorganization to Regulate Metabolic Activity in Brown Adipose Tissue

Li Yue, Imai Norihiro, Goyal Samaksh, Nicholls Hayley, Krisko Tibor, Baqai Mahnoor, Ang Lay-Hong, Tillman Matthew, Ortlund Eric, Cohen David, Hagen Susan

FASEB JOURNAL 2020年4月

　詳細を見る

会議種別：口頭発表（一般）
Them1 Binds to Free Fatty Acids and is Allosterically Regulated by Lysophosphatidylcholine to Control Fatty Acyl-CoA Hydrolysis in Brown Adipose Tissue

Tillman Matthew, Li Yue, Khadka Manoj, Imai Norihiro, Adhiyaman Akshitha, Juneja Puneet, Hagen Susan, Cohen David, Ortlund Eric

FASEB JOURNAL 2020年4月

　詳細を見る

会議種別：口頭発表（一般）
IMPROVEMENT OF LIVER FUNCTIONAL RESERVE AFTER SVR IN HCV-PATIENTS WITH COMPENSATED, SEVERE FIBROSIS BY IFN-FREE, DAA COMBINATION TREATMENT-IMPACT OF PRETREATMENT SERUM AFP LEVELS

Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

HEPATOLOGY 2020年11月

　詳細を見る

会議種別：口頭発表（一般）

▼全件表示

講演・口頭発表等の先頭へ▲

科研費 3

臓器特異的なUBXD8の機能を主軸としたアルコール性肝障害の病態形成メカニズム

研究課題/研究課題番号：21KK0277 2021年

科学研究費助成事業国際共同研究加速基金(国際共同研究強化(A))

今井則博

　詳細を見る

担当区分：研究代表者

配分額：15600000円（直接経費：12000000円、間接経費：3600000円）
アルコール性肝障害におけるUBXD8機能の解明

研究課題/研究課題番号：21K15946 2021年4月 - 2025年3月

若手研究

今井則博

　詳細を見る

担当区分：研究代表者

配分額：4680000円（直接経費：3600000円、間接経費：1080000円）
マイオカインによる臓器相関に着目した新規NAFLD治療ターゲットの探索

研究課題/研究課題番号：20K22898 2020年9月 - 2022年3月

日本学術振興会科学研究費助成事業研究活動スタート支援研究活動スタート支援

今井則博

　詳細を見る

担当区分：研究代表者

配分額：2860000円（直接経費：2200000円、間接経費：660000円）

骨格筋はマイオカインと総称されるペプチドの分泌を通じて、肝臓を含む全身の代謝臓器との臓器間コミュニケーションにおいて重要な役割を果たしている。近年、研究代表者はマウスモデルにおいて骨格筋における脂肪酸のβ酸化が臓器を超えて脂肪肝、インスリン抵抗性、肥満の発症に関与していること、また骨格筋が代謝状態に応じて複数のマイオカインを分泌し肝臓からの超低密度リポタンパク質(VLDL)分泌を調節していることを明らかにした。これらの知見は骨格筋の脂肪酸代謝が全身の糖代謝、脂質代謝において重要な役割を果たしていること、骨格筋がマイオカインを通じて過栄養時の脂肪肝、肥満の発症に寄与していることを示唆している。

researchmap

科研費の先頭へ▲